Thailand approves NERLYNX for HER2+ breast cancer: Will it change relapse prevention?
NERLYNX launches in Thailand for HER2+ breast cancer. Find out how neratinib could reshape relapse prevention and treatment sequencing across Southeast Asia.
Pharma & Biotech